XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Reporting (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Profitability that are Most Relied Upon by the Codm are Gross Revenue and Net Loss | The measures of segment profitability that are most relied upon by the CODM are gross revenue and net loss, as presented within the table below and reconciled to the statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.
|  | Three Months Ended June 30, 2025 |
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 34,095 |  |  | $ | - |  |  | $ | 34,095 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 30,540 |  |  |  | 19,752 |  |  |  | 50,292 |
Professional and consulting fees |  |  | 711 |  |  |  | 495 |  |  |  | 1,206 |
Data processing |  |  | 177 |  |  |  | - |  |  |  | 177 |
Other (income)/expenses |  |  | (742 | ) |  |  | 2,588 |  |  |  | 1,846 |
Loss from operations |  |  | 3,409 |  |  |  | (22,835 | ) |  |  | (19,426 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 364 |  |  |  | - |  |  |  | 364 |
Gain on marketable securities |  |  | 4,236 |  |  |  | 806 |  |  |  | 5,042 |
Change in fair value of investments |  |  | - |  |  |  | 31,680 |  |  |  | 31,680 |
Total other (expenses) income |  |  | 4,600 |  |  |  | 32,486 |  |  |  | 37,086 |
Net gain |  | $ | 8,009 |  |  | $ | 9,651 |  |  | $ | 17,660 |
Noncontrolling interests |  |  | 1,050 |  |  |  | - |  |  |  | 1,050 |
Net gain attributable to common stock holders of Dominari Holdings |  |  | 6,959 |  |  |  | 9,651 |  |  |  | 16,610 |
Total assets |  |  | 44,976 |  |  |  | 63,312 |  |  |  | 108,288 |
|  | Six Months Ended June 30, 2025 |
|  | Dominari |  |  | Legacy AIkido |  |  |  |
|  | Financial |  |  | Pharma |  |  | Consolidated |
Revenue |  | $ | 42,206 |  |  | $ | - |  |  | $ | 42,206 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 37,430 |  |  |  | 48,557 |  |  |  | 85,987 |
Professional and consulting fees |  |  | 1,358 |  |  |  | 1,269 |  |  |  | 2,627 |
Data processing |  |  | 359 |  |  |  | - |  |  |  | 359 |
Other expenses |  |  | 733 |  |  |  | 3,936 |  |  |  | 4,669 |
Loss from operations |  |  | 2,326 |  |  |  | (53,762 | ) |  |  | (51,436 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 381 |  |  |  | 42 |  |  |  | 423 |
Gain on marketable securities |  |  | 3,326 |  |  |  | 638 |  |  |  | 3,964 |
Unrealized loss on note receivable |  |  | - |  |  |  | 221 |  |  |  | 221 |
Change in fair value of investments |  |  | - |  |  |  | 32,000 |  |  |  | 32,000 |
Total other (expenses) income |  |  | 3,707 |  |  |  | 32,901 |  |  |  | 36,608 |
Net loss |  | $ | 6,033 |  |  | $ | (20,861 | ) |  | $ | (14,828 | )
Noncontrolling interests |  |  | 1,050 |  |  |  | - |  |  |  | 1,050 |
Net gain attributable to common stock holders of Dominari Holdings |  |  | 4,983 |  |  |  | (20,861 | ) |  |  | (15,878 | )
Total assets |  |  | 44,976 |  |  |  | 63,312 |  |  |  | 108,288 |
|  | Three Months Ended June 30, 2024 |
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 5,503 |  |  | $ | 671 |  |  | $ | 6,174 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 4,962 |  |  |  | 1,725 |  |  |  | 6,687 |
Professional and consulting fees |  |  | 293 |  |  |  | 168 |  |  |  | 461 |
Data processing |  |  | 227 |  |  |  | 12 |  |  |  | 239 |
Other expenses |  |  | 847 |  |  |  | 676 |  |  |  | 1,523 |
Loss from operations |  |  | (826 | ) |  |  | (1,910 | ) |  |  | (2,736 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 205 |  |  |  | 80 |  |  |  | 285 |
Gain on marketable securities |  |  | - |  |  |  | 104 |  |  |  | 104 |
Unrealized loss on note receivable |  |  | - |  |  |  | (742 | ) |  |  | (742 | )
Change in fair value of investments |  |  | - |  |  |  | (3,031 | ) |  |  | (3,031 | )
Total other (expenses) income |  |  | 205 |  |  |  | (3,589 | ) |  |  | (3,384 | )
Net loss |  | $ | (621 | ) |  | $ | (5,499 | ) |  | $ | (6,120 | )
Total assets |  |  | 17,361 |  |  |  | 31,712 |  |  |  | 49,073 |
|  | Six Months Ended June 30, 2024 |
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 6,870 |  |  | $ | 671 |  |  | $ | 7,541 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 6,384 |  |  |  | 2,452 |  |  |  | 8,836 |
Professional and consulting fees |  |  | 761 |  |  |  | 657 |  |  |  | 1,418 |
Data processing |  |  | 375 |  |  |  | 45 |  |  |  | 420 |
Other expenses |  |  | 1,370 |  |  |  | 1,038 |  |  |  | 2,408 |
Loss from operations |  |  | (2,020 | ) |  |  | (3,521 | ) |  |  | (5,541 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 341 |  |  |  | 108 |  |  |  | 449 |
Gain on marketable securities |  |  | - |  |  |  | 678 |  |  |  | 678 |
Unrealized loss on note receivable |  |  | - |  |  |  | (1,657 | ) |  |  | (1,657 | )
Change in fair value of investments |  |  | - |  |  |  | (5,490 | ) |  |  | (5,490 | )
Total other (expenses) income |  |  | 341 |  |  |  | (6,361 | ) |  |  | (6,020 | )
Net loss |  | $ | (1,679 | ) |  | $ | (9,882 | ) |  | $ | (11,561 | )
Total assets |  |  | 17,361 |  |  |  | 31,712 |  |  |  | 49,073 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration